Notice Number: NOT-DA-19-063
Key Dates
Release Date: July 19, 2019
PAR-18-901
Issued by
National Institute on Drug Abuse (NIDA)
Purpose
The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in Funding Opportunity Announcement (FOA) PAR-18-901 “Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional).”
The following sections of PAR-18-901 have been updated to reflect the participation of NIDA in this FOA.
Part 1. Overview Information
The following information has been added:
Components of Participating Organizations
Fogarty International Center (FIC)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Aging (NIA)
National Institute on Dental and Craniofacial Research (NIDCR)
National Institute on Drug Abuse (NIDA)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.989, 93.853, 93.242, 93.213, 93.113, 93.866, 93.121, 93.279
Part 2. Section I. Funding Opportunity Description
The following information has been added:
NIH IC Partner Interests
National Institute on Drug Abuse (NIDA)Research priority areas have been identified that are international in scope, are associated with substantial detrimental health consequences, and for which international collaborative research may provide a unique opportunity to expand our knowledge and ability to effectively respond. The following areas of research are current priority areas:
Opioid overdose and addiction have been increasing in the United States and other countries, with synthetic opioids accounting for an increasing share of these problems. Studies are needed regarding trans-national drug markets for synthetic and other opioids, novel approaches to preventing opioid use, injection, and overdose, and novel approaches to treating opioid addiction and delivering services to reduce opioid use and its infectious disease consequences on a population basis.
Research on marijuana, its acute and chronic effects, especially on the neurobiology and function of the brain, are encouraged. In addition, research on the impacts of policies and laws regarding marijuana possession and use are encouraged.
Active drug use, across a variety of substances and modes of administration, is often associated with increased risk of HIV transmission, non-adherence to antiretrovirals (ARVs), or lapses in HIV treatment participation. Studies are needed to discern the best strategy to reach and test high-risk individuals and initiate and monitor ARV therapy for those who test positive
Abuse of Amphetamine-type stimulants, in particular cocaine, methamphetamine, and new psychoactive substances also called synthetic or designer drugs is a growing problem in the United States and in many other countries. Studies are encouraged to assess the nature and extent of stimulant use (including patterns of distribution), their public health consequences and novel approaches to prevention and treatment of stimulant use. Studies are also encouraged that increase our understanding of designer drugs, including their short- and long-term sequelae, the course of designer drug use and abuse, as well as prevention and treatment approaches and the character of transnational drug markets for these substances.
Inhalant abuse continues to be an under-recognized public health problem in many countries. Studies are encouraged to improve epidemiological data on the nature and extent of abuse, to develop and implement effective prevention programs, to better understand the neurobiological impacts of these agents, and to increase public awareness of their impact.
Smoking during pregnancy studies are encouraged to increase our knowledge of the prenatal impact of smoking and the effects of early exposure to tobacco and marijuana in young people and adolescents on development of addiction and other diseases and on cognitive development.
Drugged driving studies are encouraged to develop and utilize accurate drug testing technologies to assess the prevalence of driving under the influence of drugs, the role of drugs in accidents, and to assess the costs and benefits of laws and other programs to reduce the incidence and impact of drugged driving.
Section VII. Agency Contacts
The following contacts have been added:
Scientific/Research Contacts
Steven Gust, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301 402 1118
Email: sgust@nih.gov
Financial/Grants Management
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301 480 1159
Email: pfleming@mail.nih.gov
All other aspects of this FOA remain the same.
Inquiries
Please direct all inquiries to:
Steven Gust, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301 402 1118
Email: sgust@nih.gov
and Human Services (HHS)
